Related references
Note: Only part of the references are listed.Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)
Sue S. Yom et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Head and Neck Cancers, Version 2.2020
David G. Pfister et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus?Associated Oropharyngeal Squamous Cell Carcinoma
Bhishamjit S. Chera et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
Hisham Mehanna et al.
LANCET (2019)
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
Maura L. Gillison et al.
LANCET (2019)
Mature Results of a Prospective Study of Deintensified Chemoradiotherapy for Low-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma
Bhishamjit S. Chera et al.
CANCER (2018)
The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era
Zachary S. Zumsteg et al.
CANCER (2017)
Treatment at High-Volume Facilities and Academic Centers Is Independently Associated With Improved Survival in Patients With Locally Advanced Head and Neck Cancer
John M. David et al.
CANCER (2017)
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial
Stefano Maria Magrini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Randomized Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Long-Term Report of Efficacy and Toxicity
Phuc Felix Nguyen-Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC)
Lauren Q. Shapiro et al.
ORAL ONCOLOGY (2014)
A comparison of 12 algorithms for matching on the propensity score
Peter C. Austin
STATISTICS IN MEDICINE (2014)
Enhanced Radiation Sensitivity in HPV-Positive Head and Neck Cancer
Randall J. Kimple et al.
CANCER RESEARCH (2013)
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
Anil K. Chaturvedi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site
Pierre Blanchard et al.
RADIOTHERAPY AND ONCOLOGY (2011)
MATURE RESULTS OF A RANDOMIZED TRIAL OF ACCELERATED HYPERFRACTIONATED VERSUS CONVENTIONAL RADIOTHERAPY IN HEAD-AND-NECK CANCER
Michele I. Saunders et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
Lester J. Peters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis
Mitchell Machtay et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Concomitant radiochemotherapy or accelerated radiotherapy: Analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC)
J Bourhis et al.
SEMINARS IN ONCOLOGY (2004)
Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma
F Denis et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial
J Overgaard et al.
LANCET (2003)
Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer
DJ Adelstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
